Such an effect of PARPi and ATRi has been reported in other preclinical models with high replication stress [reviewed in Chabanon and colleagues (60)] and in clinical studies evaluating ATRi, notably in non–small cell lung cancer (NSCLC) and melanoma, in which they can potentiate or revert resistance to anti–PD-L1, respectively (61–63). Here, CD274 is linked to lung cancer.